ArticleFrontiers in immunology2025
The key role of DLX6 in nasopharyngeal carcinoma: metastasis, angiogenesis and tumor immune mechanism.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- T cell fate regulation in EBV‑associated nasopharyngeal carcinoma (Review).Oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Precise management of gene expression is vital for the correct growth and operational efficiency of cells. Early-stage nasopharyngeal carcinoma (NPC) often presents asymptomatically, leading to delayed diagnosis, limited treatment options, and increased risk of recurrence and metastasis. This study investigates the role of DLX6 in NPC pathogenesis to enhance early screening and treatment. Methods and materials: Immunohistochemistry and RNA sequencing were utilized to investigate the relationship between DLX6 expression in NPC tumor samples and clinical pathological factors. Clinical data from Fujian Cancer Hospital, along with sequencing analysis from the GEO databases, were used for bioinformatics analysis. NPC cell lines with DLX6 knockdown were established, and the impact of DLX6 on the biological traits of NPC cells was assessed through wound healing, transwell, colony formation, and EdU assays. The expression of EMT-related proteins and the PI3K-AKT pathways was examined using western blot analysis. Results: Immunohistochemistry validated the association between DLX6 and NPC prognosis, whereas RNA sequencing illustrated its expression levels in tissues and cells. Functional assays such as wound healing, transwell, and colony formation revealed that DLX6 knockdown adversely affected NPC cell proliferation, invasion, and migration. Bioinformatics analysis revealed that DLX6 is involved in pathways related to cell cycle, DNA replication, and cancer progression. Immune infiltration analysis showed that DLX6 expression affects the immune landscape in NPC, correlating positively with DC and TH17 cells, and negatively with cytotoxic T cells and B cells. Low DLX6 expression was associated with higher levels of chemokines and better immunotherapy outcomes. Conclusion: Our study indicates that DLX6 is a novel prognostic biomarker and potential therapeutic target for NPC, playing a critical role in metastasis, angiogenesis, and tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.